⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22754050 | 0.76 | — | — | |
| SCHEMBL21547908 | 0.73 | — | — | |
| SCHEMBL18650008 | 0.68 | NPC1 (0.30) | — | |
| SCHEMBL1391755 | 0.67 | — | — | |
| SCHEMBL15564229 | 0.67 | — | — | |
| SCHEMBL11482964 | 0.67 | — | — | |
| SCHEMBL5151010 | 0.66 | — | — | |
| SCHEMBL22332006 | 0.62 | — | — | |
| SCHEMBL18610693 | 0.62 | — | — | |
| SCHEMBL8570593 | 0.62 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-07-06 | — | — | US | disclosed |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2020-08-13 | — | — | US | disclosed |
| US-20190225588-A1 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LTD (AU) | 2019-07-25 | — | — | US | disclosed |